Utility of Cilefa Pink B, a foodstuff dye as a fluoro-substrate in the devising of the first facile green Molecular-mass-Related Fluorescence Sensor for quantifying amlodipine in batched material and dosage forms; content uniformity evaluation

This study introduces the first and unique Molecular-mass-Related Fluorescence Sensor as the first fluorimetric strategy for determining amlodipine. An environmentally friendly, single-step, and direct spectrofluorimetric approach was utilized to evaluate the analyte. In an acidic setting, combining the amlodipine medication and the fluorescent dye Cilefa Pink B generated an instantaneous ultra-fluorescent product. An increase in dye response after adding amlodipine was proportional to the molecular weight of the generated complex, as measured at 329 nm. was the idea ofthe applied fluorimetric analysis. The complexing process increased the molecular mass from 879.86 to 1288.739 g mol-1. The medication's range of 0.050-1.00 µg mL-1 is directly correlated with this molecular massenlargement. The ideal settings for the changeable parameters of the system were established through an analysis of the response of the amlodipine-Cilefa Pink B system. Furthermore, the developed sensor complied with ICH (International Council for Harmonization) standards. The sensitivity limits were 0.0139 µg mL-1 (for the detection limit, LOD) and 0.042 µg mL-1 (for the quantification limit, LOQ). Additionally, this method effectively recovered the drug in its original and therapeutic dosage forms. Finally, the proposed process's environmental impact was also assessed through different modern greenness evaluation tools.

Utility of Cilefa Pink B, a food dye in a facile decoration of the first green molecular-size-based fluorescence probe (MSBFP) for determining trimebutine; application to bulk, dosage forms, and real plasma

This research presents the first novel green molecular-size-based fluorescence probe (MSBFP) as a spectroscopic strategy for detecting the Trimebutine drug. The method used a green, one-pot, direct spectrofluorimetric methodology to validate and assess the medication. Trimebutine drug and Cilefa Pink B formed an immediate ultra-fluorescent complex when mixed in an acidic environment. The fluorimetric study relied on Trimebutine's amplification of the dye response, which correlated to the generated complex's molecular size at 361 nm. Upon complexation, the molecular mass has grown from 504.5 to 1384.4 g mol^-1. This growth is proportionally coupled to the drug concentration range of 0.035-1.5 µg mL^-1. The lower and upper limits of the sensitivity varied from 0.010 and 0.029 µg mL^-1, respectively. Trimebutine-Cilefa Pink B complexes were analyzed to determine optimal values for all the tunable system variables. Also, The International Council for Harmonization (ICH) requirements were successfully met by the system. In addition, this method effectively retrieved the drug in the intended pharmaceutical dosages. A significant achievement was using the developed fluorimetric method to monitor the drug of interest in human biofluids. The environmental friendliness of the planned procedure was then evaluated.